Kathryn E. Beckermann

7.8k total citations
57 papers, 2.0k citations indexed

About

Kathryn E. Beckermann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Kathryn E. Beckermann has authored 57 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Kathryn E. Beckermann's work include Renal cell carcinoma treatment (26 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Cancer Genomics and Diagnostics (13 papers). Kathryn E. Beckermann is often cited by papers focused on Renal cell carcinoma treatment (26 papers), Cancer Immunotherapy and Biomarkers (26 papers) and Cancer Genomics and Diagnostics (13 papers). Kathryn E. Beckermann collaborates with scholars based in United States, France and Denmark. Kathryn E. Beckermann's co-authors include W. Kimryn Rathmell, Jeffrey C. Rathmell, Stephanie O. Dudzinski, Benjamin G. Vincent, Melissa M. Wolf, Douglas B. Johnson, Peter J. Siska, Scott M. Haake, Brian I. Rini and Christof C. Smith and has published in prestigious journals such as Cell, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Kathryn E. Beckermann

51 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kathryn E. Beckermann United States 23 920 898 679 622 483 57 2.0k
Géraldine Gentric France 13 752 0.8× 951 1.1× 408 0.6× 180 0.3× 602 1.2× 17 1.8k
Jianjie Zhu China 25 864 0.9× 1.1k 1.2× 526 0.8× 437 0.7× 713 1.5× 63 2.1k
Silvestre Vicent Spain 24 721 0.8× 1.1k 1.3× 361 0.5× 477 0.8× 411 0.9× 40 2.0k
Yanis Boumber United States 22 699 0.8× 1.6k 1.7× 192 0.3× 420 0.7× 471 1.0× 56 2.3k
Taher Al‐Tweigeri Saudi Arabia 24 1.7k 1.9× 619 0.7× 729 1.1× 354 0.6× 553 1.1× 61 2.5k
Hirokazu Okayama Japan 30 962 1.0× 1.3k 1.4× 604 0.9× 392 0.6× 721 1.5× 92 2.4k
Daniele Fanale Italy 29 979 1.1× 1.2k 1.4× 274 0.4× 437 0.7× 922 1.9× 84 2.5k
Gui‐Yan Xie China 7 381 0.4× 870 1.0× 315 0.5× 506 0.8× 463 1.0× 13 1.4k
Ergin Kilic Germany 27 479 0.5× 1.3k 1.5× 202 0.3× 748 1.2× 980 2.0× 70 2.4k

Countries citing papers authored by Kathryn E. Beckermann

Since Specialization
Citations

This map shows the geographic impact of Kathryn E. Beckermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn E. Beckermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn E. Beckermann more than expected).

Fields of papers citing papers by Kathryn E. Beckermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn E. Beckermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn E. Beckermann. The network helps show where Kathryn E. Beckermann may publish in the future.

Co-authorship network of co-authors of Kathryn E. Beckermann

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn E. Beckermann. A scholar is included among the top collaborators of Kathryn E. Beckermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn E. Beckermann. Kathryn E. Beckermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Srinivasan, Ramaprasad, Othon Iliopoulos, Kathryn E. Beckermann, et al.. (2025). Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. The Lancet Oncology. 26(5). 571–582. 2 indexed citations
3.
Brugarolas, James, Kathryn E. Beckermann, Brian I. Rini, et al.. (2024). A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma. Clinical Cancer Research. 30(11). 2402–2411. 12 indexed citations
4.
Else, Tobias, Eric Jonasch, Othon Iliopoulos, et al.. (2024). Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clinical Cancer Research. 30(9). 1750–1757. 11 indexed citations
5.
Ornstein, Moshe Chaim, Wei Wei, C. Marcela Díaz‐Montero, et al.. (2024). Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clinical Genitourinary Cancer. 22(6). 102181–102181.
6.
Iliopoulos, Othon, Vivek Narayan, Kathryn E. Beckermann, et al.. (2024). Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study. The Lancet Oncology. 25(10). 1325–1336. 16 indexed citations
7.
Beckermann, Kathryn E., Aviva G. Asnis-Alibozek, Michael B. Atkins, et al.. (2024). Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. The Oncologist. 29(3). 254–262. 8 indexed citations
8.
Choueiri, Toni K., Laurence Albigès, Philippe Barthélémy, et al.. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. The Lancet. 404(10460). 1309–1320. 32 indexed citations
9.
Narayan, Vivek, Othon Iliopoulos, Benjamin L. Maughan, et al.. (2023). SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY. Neuro-Oncology Advances. 5(Supplement_3). iii31–iii31. 1 indexed citations
10.
11.
Chen, Yu‐Wei, Brian I. Rini, & Kathryn E. Beckermann. (2022). Emerging Targets in Clear Cell Renal Cell Carcinoma. Cancers. 14(19). 4843–4843. 16 indexed citations
12.
13.
Obradović, Aleksandar, Nivedita Chowdhury, Scott M. Haake, et al.. (2021). Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 184(11). 2988–3005.e16. 191 indexed citations
14.
Satkunasivam, Raj, Zachary Klaassen, Mary E. Hall, et al.. (2021). Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. Urologic Oncology Seminars and Original Investigations. 40(2). 64.e17–64.e24. 1 indexed citations
15.
Zhao, Jeffrey, et al.. (2021). Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Expert Review of Precision Medicine and Drug Development. 6(4). 281–294. 8 indexed citations
16.
Beckermann, Kathryn E., Rachel A. Hongo, Xiang Ye, et al.. (2020). CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight. 5(16). 72 indexed citations
17.
Jiang, Xiaoyu, Stephanie O. Dudzinski, Kathryn E. Beckermann, et al.. (2020). MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer. 8(1). e000328–e000328. 43 indexed citations
18.
Wolf, Melissa M., W. Kimryn Rathmell, & Kathryn E. Beckermann. (2020). Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene. 39(17). 3413–3426. 111 indexed citations
19.
Siska, Peter J., Kathryn E. Beckermann, Frank M. Mason, et al.. (2017). Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2(12). 274 indexed citations
20.
Rai, Robba, Jennifer L. McQuade, Jeffrey A. Sosman, et al.. (2016). Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma. Annals of Oncology. 27. vi381–vi381. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Géraldine Gentric Breakdown of academic impact, for papers by Jianjie Zhu Breakdown of academic impact, for papers by Silvestre Vicent Breakdown of academic impact, for papers by Yanis Boumber Breakdown of academic impact, for papers by Taher Al‐Tweigeri Breakdown of academic impact, for papers by Hirokazu Okayama Breakdown of academic impact, for papers by Daniele Fanale Breakdown of academic impact, for papers by Gui‐Yan Xie Breakdown of academic impact, for papers by Ergin Kilic
Rankless by CCL
2026